Top Markets
Coin of the day
Genflow Biosciences Plc Genflow Biosciences Plc

Genflow Biosciences Plc

GENF
Rankning i aktier #40421
Genflow Biosciences plc, together with its subsidiaries, engages in the... Genflow Biosciences plc, together with its subsidiaries, engages in the research and development of gene therapy targeting the upstream biology of aging in the United Kingdom and Belgium. The company operates as a pre-clinical biotechnology company that focuses on developing biological interventions aimed at tackling the effects of aging, slowing, and halting the aging process, as well as reducing the incidence of age-related diseases. Its lead drug candidate is GF-1002, a suspension of an adeno-associated viral vector-based gene therapy for intravenous infusion. The company is also developing GF-1003, a topical delivery of SIRT6 to the fibroblasts in the skin; GF-1004, a non-human pipeline anti-aging for veterinary use; GF-1005, which addresses mitochondrial dysfunction observed in sarcopenia for muscle health and combat sarcopenia; and GF-1006, an ophthalmology mRNA cent SIRT6 for the treatment of cornea pathologies and glaucoma. The company has collaborative research agreements with Revatis SA and EXO Biologics for therapy medicinal products. Genflow Biosciences plc was founded in 2020 and is headquartered in London, the United Kingdom.
Aktiekurs
$0.02653368
Marknadsvärde
$150.29K
Förändring (1 dag)
-4.41%
Förändring (1 år)
194.29%
Land
GB
Handel Genflow Biosciences Plc (GENF)

Kategori

P/B-tal för Genflow Biosciences Plc (GENF)
P/B-tal per 2026 TTM: 0
Enligt Genflow Biosciences Plc senaste finansiella rapporter och aktiekurs är det aktuella P/B-talet (TTM) 0. I slutet av 2026 hade företaget ett P/B-tal på 0.
Historik för P/B-tal för Genflow Biosciences Plc från 2026 till 2026
P/B-tal vid årets slut
År P/B-tal Ändra
Inte tillräckligt med data för de angivna datumen.
P/B-tal för liknande företag eller konkurrenter
Företag P/B-tal Skillnad i P/B-tal Land
6.2613 -
US
6.3483 -
NL
- -
CH
- -
KR
3.634 -
BE